33,804 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Great Lakes Advisors LLC

Great Lakes Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 33,804 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,146,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cardinal Capital Management raised its stake in Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 0.3% in the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after buying an additional 73 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 81 shares during the period. Pinnacle Associates Ltd. grew its holdings in shares of Jazz Pharmaceuticals by 0.7% in the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after acquiring an additional 83 shares during the period. Finally, Fifth Third Wealth Advisors LLC increased its position in Jazz Pharmaceuticals by 4.4% during the first quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock valued at $377,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the sale, the director directly owned 9,680 shares in the company, valued at approximately $2,231,724. This represents a 10.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the sale, the director owned 360,682 shares of the company’s stock, valued at $91,245,332.36. The trade was a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,098 shares of company stock worth $4,649,786 in the last three months. 4.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JAZZ shares. TD Cowen increased their price objective on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Royal Bank Of Canada upped their target price on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Leerink Partners increased their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Finally, Canaccord Genuity Group began coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $290.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $272.89.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $252.16 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The company has a market cap of $16.37 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.23 and a beta of 0.32. The firm’s fifty day moving average is $244.06 and its two-hundred day moving average is $214.43. Jazz Pharmaceuticals PLC has a 52-week low of $118.04 and a 52-week high of $265.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same period last year, the company earned ($8.25) earnings per share. The firm’s revenue was up 15.5% on a year-over-year basis. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 21.66 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.